Leukoreduced Whole Human Blood
Whole human blood with leukocytes filtered to <5x10^6 per unit to reduce transfusion reactions, still classified as whole blood under HTS 3002.90.52.10 since primary components remain intact.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If further processed into packed red cells
Centrifugation and plasma removal converts whole blood to red blood cell concentrates under specific subheadings.
If packaged in first-aid kits
Chapter note 3006 includes first-aid boxes containing blood products, classifying the kit assembly separately.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Provide leukoreduction process validation and white cell count test results as part of import dossier
• Label units clearly with AB0/Rh type, expiration, and processing date per FDA cGMP requirements
Related Products under HTS 3002.90.52.10
Whole Human Blood for Transfusion
Whole human blood collected from donors, anticoagulated, and prepared for direct transfusion into patients experiencing acute blood loss or anemia. It falls under HTS 3002.90.52.10 as whole human blood intended for therapeutic uses without separation into components like plasma or platelets.
Anticoagulated Whole Human Blood Units
Standard 450-500mL units of human whole blood treated with CPD or CPDA-1 anticoagulant, stored in PVC blood bags for emergency transfusions. Classified under HTS 3002.90.52.10 as unmodified whole human blood for therapeutic transfusion purposes.
O-Negative Whole Human Blood for Emergencies
Universal donor O-negative whole human blood, group-typed and cross-matched, for immediate use in trauma cases without compatibility testing. HTS 3002.90.52.10 covers this as therapeutic whole human blood not separated into fractions.
Irradiated Whole Human Blood for Immunocompromised Patients
Gamma-irradiated whole human blood to prevent graft-vs-host disease in transplant or cancer patients, qualifying as therapeutic whole human blood under HTS 3002.90.52.10.